Abstract
Introduction To analyse the effectiveness of a dose of adenovirus vector ChAdOx1 vaccine (AVChOx1) in an outbreak of SARS-CoV-2 detected in a prison.
Methods Observational study carried out at Brians-1 Prison, Barcelona. After detecting a case of infection, rt-PCR was administered to all prisoners (some of whom had been vaccinated 21-23 days previously with a dose of AVChOx1) and to staff. Infection rates in vaccinated and unvaccinated populations were calculated, as was vaccine effectiveness.
Results One hundred and eighty-four asymptomatic prisoners (50.3% vaccinated) and 33 staff were screened. Forty-eight (25.9%) infections by the SCV-B.1.17 variant were recorded in prisoners and none in staff. Infection rates were higher in younger prisoners, immigrants, and those admitted ≥7 days previously. In all, 22.6% of vaccinated subjects were infected vs. 29.3% of unvaccinated. Vaccine effectiveness was 23%. Only 6.2 cases would have been prevented by vaccinating the unvaccinated individuals. At seven days, the rt-PCR was negative in 46.2% of vaccinated subjects vs. 13.6% of unvaccinated (p = 0.02).
Discussion In a prison outbreak, a dose of AVChAdOx1 administered 21-23 days earlier did not significantly prevent the occurrence of infections, but did reduce the duration of rt-PCR positivity. Maintaining post-vaccination preventive measures is essential.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no external funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This observational study presents the results of the rt-PCR used for screening in accordance with our clinical practice. The tests were not requested for research purposes. However, the patients were informed of the purpose of data collection and their written informed consent was requested. The study was evaluated and approved by the Clinical Research Ethics Committee of the Jordi Gol Foundation (CEI: 21/169-PCV).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Andrés Marco (amarco{at}gencat.cat); Núria Teixidó (nteixidop{at}gencat.cat); Rafael A Guerrero (rguerrero{at}gencat.cat); Lidia Puig (lidia.garcia{at}gencat.cat); Xenia Rué (xrue{at}gencat.cat); Alba Cobos (acobos{at}gencat.cat); Isabel Barnés (ibarnesv{at}gencat.cat) and Elisabet Turu (eturu{at}gencat.cat).
Contact Information: Andrés Marco, Infectious Diseases, Prison Health Program, Catalan Institute of Health, Gran Via de les Corts Catalanes, 587-589, 08004 Barcelona, Spain, Teléfono: 00349348241 00; Fax 0034934824525
Data Availability
The data that support the findings of this study are available from Prison Health Program (Catalan Institute of Health). Restrictions apply to the availability of these data as they are from the prisoners medical records, which were used under license for this study. Data are available and can be requested from Dr. Andres Marco (amarco@gencat.cat) with prior authorization from the Prison Health Program of the Catalan Health Institute.
